Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glycoimmune Checkpoint inhibitors to treat cancer. The company's proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer. By targeting multiple immune cell types, Glycoimmune Checkpoint inhibitors will tackle resistance to first-generation immuno-oncology agents, and make possible a wider range of rational combination therapies to treat cancer. While Palleon is focused primarily on oncology, the Convergence Platform is applicable to other therapeutic areas including infectious diseases, neurodegeneration, inflammation, and fibrosis.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/04/17 | $47,600,000 | Series A |
AbbVie Biotech Ventures Pfizer Venture Investments SR One Takeda Ventures Vertex Ventures | undisclosed |
| 09/17/20 | $100,000,000 | Series B |
AbbVie Biotech Ventures Matrix Capital Management  Pfizer Venture Investments SR One Surveyor Capital Takeda Ventures Vertex Ventures | undisclosed |
